Boston Scientific Q3 sales $5.065B (+20.3% reported) beat guidance; adjusted EPS $0.75 beats $0.70-0.72

BOSTON SCIENTIFIC CORP

2025-Q3 EPS reported $1.49 revenue$14,788,000,000

GAAP net income $755M ($0.51 EPS) vs $469M ($0.32) a year ago; adjusted EPS $0.75 vs $0.63.
Cardiovascular sales $3.343B (+22.4% reported); MedSurg $1.722B (+16.4%).
U.S. sales +27.0% reported; EMEA +2.6% reported but -2.0% operational due to ACURATE discontinuation.
FY2025 guidance: reported sales growth ~20%, organic ~15.5%; GAAP EPS $1.97-2.01, adjusted EPS $3.02-3.04.
Agreed to acquire Nalu Medical (neuromodulation) and acquired Elutia's antibiotic-eluting Envelope products.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.